Blue Jet Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of Rs. 60 per equity share.
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Blue Jet Healthcare's board, meeting on May 14, 2025, approved audited FY25 results showing revenue from operations of Rs 1,029.99 crore (up ~45% from Rs 711.60 crore in FY24) and net profit of Rs 305.20 crore (up ~86% from Rs 163.75 crore), with EPS at Rs 17.59 versus Rs 9.44 last year. A final dividend of Rs 1.20 per share (60% on face value of Rs 2) was recommended, subject to shareholder approval. The board also approved a proposal to raise up to Rs 1,500 crore through instruments like QIPs, preferential issues or private placements of equity or convertible securities, subject to shareholder and regulatory approvals. Separately, the company will acquire a 30,366 sq. m. industrial plot at Dahej III, Gujarat from GIDC for about Rs 11.12 crore for manufacturing, and appointed Ms. Payal Gandhi (daughter of Executive Director Mr. Naresh Shah) as Senior Management Personnel effective June 1, 2025. The auditor issued an unmodified opinion, though a Rs 193.39 crore income tax demand for AY 2020-21 to 2023-24 is under appeal, with the company having already provisioned Rs 128.74 crore and believing it has a strong case.
Strong FY25 earnings beat with revenue and profit nearly doubling support a positive view, but the Rs 1,500 crore fundraise proposal may lead to equity dilution concerns, and the open tax dispute of Rs 193.39 crore remains a watch item. The Rs 1.20 per share final dividend (up from Rs 1 in FY24) is a modest token payout given the strong earnings, while the Dahej land buy signals capacity expansion. The related-party senior management appointment may also draw governance attention.